Fig. 2From: Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP studyBest percentage change from the baseline in the sum of longest diameters of target lesions (n = 34)Back to article page